North America liver disease treatment market 2025: Industry Developments, Future Growth, Share & Industry Insights | Novo Nordisk A/S, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc

North America liver disease treatment market reached US$ 7.9 billion in 2023 and is expected to reach US$ 12.28 billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

According to DataM Intelligence Comprehensive Report has released its latest report on the "North America liver disease treatment Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/north-america-liver-disease-treatment-market?sg

Industry Latest News 2025:

✅ 2025-08-15 - FDA granted accelerated approval to Wegovy (semaglutide) for treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis.

✅ 2025-05-14 - GSK agreed to acquire efimosfermin (from Boston Pharmaceuticals) a phase-III-ready steatotic liver disease candidate - in a deal worth up to $2.0 billion.

✅ 2025-07-07 - GSK announced completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals.

✅ 2025-09-11 - Bausch Health completed the acquisition of DURECT Corporation, adding larsucosterol (an FDA Breakthrough-Therapy designated asset for alcohol-associated hepatitis) to its hepatology pipeline.

✅ 2025-10-09 - Novo Nordisk announced agreement to acquire Akero Therapeutics (developer of the FGF21 analogue efruxifermin for MASH) in a deal valued up to ~$5.2 billion.

✅ 2025 (ongoing) - Multiple late-stage/Phase-3 programs for MASH/NASH (including efruxifermin, efimosfermin, and other FGF21/incretin-class combinations) reported continued enrollment and readouts across North America in 2025.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/north-america-liver-disease-treatment-market?sg

Market Growth Drivers:

✅ Rapid increase in metabolic-associated fatty liver disease (MAFLD / previously NAFLD)

Rising rates of obesity, type 2 diabetes and metabolic syndrome are the single largest epidemiological force enlarging the pool of patients who need monitoring and treatment for fatty-liver disease and its inflammatory/fibrotic progression (MASH/NASH). Population studies show NAFLD/MASH prevalence at scale across North America, which directly expands demand for diagnostic, pharmacologic and lifestyle-intervention services.

✅ Lifestyle and alcohol-related risk factors

Harmful alcohol consumption remains a major contributor to alcohol-associated liver disease and cirrhosis; combined with obesity, alcohol produces synergistic liver damage and raises rates of advanced disease requiring specialist care. Trends in alcohol use and related mortality continue to sustain a steady need for therapeutics, hospitalization and long-term management.

✅ Greater clinical recognition, earlier diagnosis and non-invasive testing

Improved awareness among clinicians and wider adoption of non-invasive tools (fibrosis scores, elastography and advanced biomarkers) are shifting care earlier in the disease course. Earlier detection increases the number of patients entering treatment pathways (lifestyle programs, pharmacologic trials, fibrosis-directed therapies), expanding the addressable market beyond end-stage care.

✅ Regulatory approvals and a maturing therapeutic pipeline

Recent regulatory milestones including the first approvals for drugs targeting liver fibrosis/MASH have converted clinical R&D momentum into commercially available therapies. New approvals and promising mid-late stage trial results create immediate treatment demand and stimulate investment in care delivery, specialist clinics and companion diagnostics. These events both expand current market value and accelerate uptake of novel therapies.

Segments Covered in the Beverage Premix Market:

By Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy Drugs)

By Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Liver Cancer, Genetic Disorder, Others)

By End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers, Others)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=north-america-liver-disease-treatment-market?sg

Major Key Players: Pfizer Inc., AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche, Takeda Pharmaceutical Company Limited Ltd, Novo Nordisk A/S, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., Gilead Sciences Inc.

✅ Pfizer Inc. - An active clinical/pipeline player in NASH and other metabolic-liver programs (e.g., fast-track status for its ervogastat/clesacostat NASH candidate), positioning Pfizer as an emerging commercial contender in the NASH segment rather than a legacy leader in antiviral/hepatitis revenues.

✅ AbbVie Inc. - A major commercial player in hepatitis C: AbbVie's pan-genotypic MAVYRET (glecaprevir/pibrentasvir) is a top HCV product and represented a material revenue stream (reported Mavyret sales cited in company/product summaries), making AbbVie one of the largest contributors to the antiviral portion of the North America liver-disease market.

✅ Johnson & Johnson Services, Inc. (Janssen) - Maintains an ongoing hepatitis/viral-hepatitis R&D footprint and occasional clinical data releases; J&J is a significant multispecialty firm with targeted activity in hepatology (mainly via Janssen) but is better known overall for broader infectious-disease and large-scale pharma sales rather than dominating the liver-market revenue tables.

✅ Hoffmann-La Roche (Roche/Genentech) - A leading player in liver oncology (hepatocellular carcinoma) with marketed immuno-oncology combinations (e.g., atezolizumab + bevacizumab programs) and strong diagnostic/oncology positioning that makes Roche a top contributor to the liver-cancer / targeted therapy segment of the North American market.

✅ Takeda Pharmaceutical Company - Focused R&D and partnerships in gastroenterology and advanced liver disease/NASH (several collaborations and discovery programs); Takeda is an important mid-to-large participant in the emerging-therapies segment (fibrosis/NASH) rather than the incumbent antiviral revenue leader.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.